# A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine in Brazil

> **NCT05052307** · — · COMPLETED · sponsor: **Hospital Moinhos de Vento** · enrollment: 4574 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine
- **DRUG:** CoronaVac COVID-19 vaccine
- **DRUG:** ChAdOx1 nCoV-19 Covid-19 Vaccine
- **DRUG:** Ad26.COV2.S COVID-19 Vaccine

## Key facts

- **NCT ID:** NCT05052307
- **Lead sponsor:** Hospital Moinhos de Vento
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-03
- **Primary completion:** 2022-06-20
- **Final completion:** 2023-07-20
- **Target enrollment:** 4574 (ACTUAL)
- **Last updated:** 2023-11-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05052307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05052307, "A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine in Brazil". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT05052307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*